Budget impact analysis of treatment‐free remission in nilotinib‐treated Japanese chronic myeloid leukemia patients

Treatment‐free remission (TFR), in which patients discontinue pharmacotherapy and remain in molecular remission, is an emerging treatment goal for patients with chronic myeloid leukemia (CML). Attainment of TFR requires an increased frequency of molecular monitoring, to ensure that patients maintain...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamazaki, Kiyotaka, Inagaki, Naohito, Moldaver, Daniel, Viana, Ricardo, Kimura, Shinya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385357/
https://www.ncbi.nlm.nih.gov/pubmed/32324296
http://dx.doi.org/10.1111/cas.14430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385357/
https://www.ncbi.nlm.nih.gov/pubmed/32324296
http://dx.doi.org/10.1111/cas.14430

Ejemplares similares